Clinical Trial Search

Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants

Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants

Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25

Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants

Primary: Change From Baseline in Histopathology Endpoints — -45.0; -36.1; -6.0; 12.6 scores on a scale — p=0.6498

Primary: Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection — 0; 0; 0; 2 participants

Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants

Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events

Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection

Primary: Number of Participants With a Decrease in Titer of One or More DSA (Either Reduced MFI or Absence of DSA on Same Dilution) — 17 Participants

Primary: Number of Patients With Renal Allograft Rejection — 5 participant

Primary: Incidence of Acute Rejection (Banff '97) or Antibody Mediated Rejection — 2; 0; 5; 3 participants

Primary: Change From Baseline in naïve B Cells From Baseline to Week 24 — 4.0; -30.4 cells/mm^3

Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants

Primary: During Screening Phase: Incidence of Alloantibody Development — 79 participants

Primary: Overall Participant Survival at One Year Post Kidney Transplant — 4; 5 participants

Primary: Response to Bortezomib Monotherapy — 0; 0; 0; 1 participants

Primary: Serum Creatinine Concentration — 112 umol/L

Primary: The Number of Subjects With a 10% Decrease in PRA Level at Month 8. — 9 Participant

Primary: Cases of Kidney Transplant Patients With DSA — 0; 0 Participants

Primary: Patient Survival — 109; 104 Participants

Primary: Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) — -0.28; -0.46 pmol/mL — p=0.002

Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min

Primary: Number of Patients Alive — 7; 13 Participants

Primary: Proportion of Recipients Who Achieve an Antibody Response >50 U/mL After the Third Dose of mRNA COVID-19 Vaccine — 69.1 Percentage of participants with response

Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg

Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…

Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2

Primary: The Number of Polyoma BK Viremia Patients — 5 Participants

Primary: Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation — 7; 73; 3; 4 Participants — p=< 0.001